• Men and women aged 18 years or older at the time of signing informed consent.

• Able and willing to sign the informed consent form (ICF).

• Ability to comply with the trial protocol.

• Histologically confirmed Marginal Zone Lymphoma (MZL) of Extranodal Marginal Zone Lymphoma (EMZL), Nodal Marginal Zone Lymphoma (NMZL) and Splenic Marginal Zone Lymphoma (SMZL) subtypes presenting with stage I-IV disease.

• Previously untreated participants.

∙ Participants with H. pylori-positive gastric EMZL who received an initial treatment with currently accepted antibiotics may be considered eligible if, after antibiotic regimen, participant has histologically confirmed MZL.

‣ Participants who were previously treated with localized therapy (eg, radiation or surgery) and never received systemic therapy and present with recurrent disease are eligible upon histological confirmation of MZL.

• Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥1 lesion that measures \>1.5 cm in the longest diameter (LDi) and ≥1.0 cm in the longest perpendicular diameter as assessed by PET/CT, CT or MRI, especially in extranodal sites, per response criteria for lymphomas (Cheson, et al., 2014). Imaging must be conducted within 6 weeks prior to the start of therapy.

∙ Participants with skin EMZL who do not meet the radiographically measurable disease criteria described herein are eligible for participation provided that skin lesion measures ≥1.5 cm in diameter by tape measure and is documented by photo or there are ≥2 skin lesions measuring \>1 cm in diameter on the body that cannot be incorporated in one radiation field and at least one of them is histologically confirmed as MZL.

‣ Participants with gastric EMZL histologically confirmed and need therapy but do not have measurable disease and in which response to treatment can be assessed by multiple random gastric biopsies per Groupe d'Etude des Lymphomes de l'Adult (GELA) criteria (Ruskoné Fourmestraux, et al., 2011).

‣ Participants with conjunctival EMZL who do not meet the radiographically measurable disease criteria described herein are eligible for participation provided that conjunctival lesion measures ≥1 cm in diameter by tape measure and is documented by photo or there are multiple conjunctival lesions measuring together \>1.5 cm that cannot be treated by radiation because of previous radiation therapy, contraindications to radiation and patient refusal to receive radiation therapy. At least one of these lesions needs to be histologically confirmed as MZL.

‣ Participants with splenic MZL who do not meet the radiographically measurable disease criteria described herein are eligible for participation provided that bone marrow (BM) infiltration of MZL is histologically confirmed.

• Participants will be asked to provide a lymph node or tissue biopsy from the most recent available archival tissue or undergo an incisional or excisional lymph node or tissue biopsy but this is not an exclusion criteria.

• a. Participants with splenic MZL who do not have a tumor to biopsy or an archival tumor tissue sample are eligible for participation provided participant is willing to undergo a BM biopsy or provide an archival BM biopsy that was obtained before the date of the first dose of study treatment; BM sample must show histologically confirmed infiltration of MZL

• Participant should have at least one of the following criteria for treatment initiation:

‣ Threatened extranodal organ function, especially for extranodal MZL

⁃ Involvement of ≥3 nodal sites, each with diameter of ≥3 cm

⁃ Any nodal or extranodal tumor mass with a diameter of ≥5 cm

⁃ B symptoms (fever ≥38 degrees Celsius of unclear etiology, night sweats, weight loss \>10% within the prior 6 months) or other symptoms attributed to disease or specific organ involvement.

⁃ Risk of local compressive symptoms that may result in organ compromise

⁃ Splenomegaly \>13 cm or splenic lesion without splenomegaly and needs treatments (e.g., symptoms, cytopenias \[hemoglobin (HgB) \<10 g/dL and platelet count ≤ 80 × 10\^9 platelets/L attributable to lymphoma bone marrow infiltration, splenomegaly or autoimmunity\], \>5,000 lymphoma cells/mm3).

⁃ Threatened organ function, especially for extranodal MZL

⁃ Leukopenia attributed to MZL (leukocytes \<1,000 cells/mm3)

⁃ Leukemia (\>5,000 lymphoma cells/mm3)

⁃ Requirement for transfusion or growth factor support attributed to lymphoma

⁃ Involvement of 2 or more extranodal sites, with tumor/lesion in each extranodal site ≥1 cm

• Life expectancy \>3 months.

⁃ Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

⁃ Adequate hematologic, hepatic, and renal function tested within 6 weeks prior to the start of therapy (values must not be achieved with growth factors):

• Absolute neutrophil count (ANC) ≥1.0 × 10\^9 cells/L.

∙ Hemoglobin ≥8.0 g/dL.

∙ Platelet count ≥50 × 10\^9 platelets/L.

∙ Total bilirubin ≤1.5 × upper limit of normal (ULN) unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin or lymphoma involvement of the liver and total bilirubin if ≤5 x ULN.

∙ Alanine transaminase (ALT)/aspartate aminotransferase (AST) ≤3.0 × ULN or ≤5 × ULN in the presence of liver involvement by lymphoma.

∙ Creatinine within normal institutional limits, or

‣ calculated creatinine clearance ≥35 mL/min by the Cockcroft-Gault Equation (Cockcroft, 1976)

⁃ estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 using the Modification of Diet in Renal Disease formula for participants with creatinine levels above institutional normal (unless due to lymphoma)

⁃ Willingness to avoid pregnancy during the trial and for at least 90 days after the last dose of the trial intervention. For more information on Contraception, please see Section 5.12.